Mr. Shah joined Domain Associates in 2006 and became a Principal in 2007. He serves as a co-founder and on the board of Zyga Technologies, on the boards of Apnex Medical, Foundry Newco 12, Miramar Labs, and Sequent Medical, and as an observer at NeuroPace, REVA Medical, ReVision Optics, Sequel Pharmaceuticals, Tandem Diabetes, and Zogenix. From 2002 to 2006, Mr. Shah was a part of the investment team at venture firm Cutlass Capital where he was involved with that firm’s investments in Apneon, GI Dynamics, Titan Health, and TranS1. From 1998 to 2002, Mr. Shah worked at Alex. Brown & Sons (now Deutsche Bank) serving as a member of the medical device equity research team. He covered the full spectrum of the medical device industry, with a particular emphasis on the cardiovascular, orthopedics/spine, and respiratory segments of the market. While in school, Mr. Shah worked as part of the growth equity team at Alex. Brown Capital Advisory & Trust. He also spent time at Johns Hopkins Hospital supporting a project that aimed to map the functional areas of the brain.